Try our Advanced Search for more refined results
Private Equity
Private Equity Law360 provides breaking news and analysis on private equity deals and the attorneys involved. Coverage includes high-impact deals, related litigation and enforcement actions, and policy developments that affect private equity firms.
Sign up for a 7-day FREE trial today!
Latest News in Private Equity
-
March 19, 2026
Fed. Circ. Rejects Last Challenge To Squire's Discretion
The Federal Circuit on Thursday shot down Volkswagen's mandamus petition claiming that the U.S. Patent and Trademark Office director shouldn't have "unfettered discretion" to deny Patent Trial and Appeal Board challenges, closing the last of 14 related appeals.
-
March 19, 2026
Tulane Panel Flags Growing Political Influence On Dealmaking
At the annual Tulane Corporate Law Institute on Thursday, panelists warned that politics is increasingly shaping dealmaking and complicating how transactions are negotiated and executed, with one likening the discussion to a "hostage" situation.
-
March 19, 2026
6 Noteworthy Changes From SEC Enforcement Manual Update
Recent updates to the U.S. Securities and Exchange Commission’s enforcement manual represent a commitment to transparency and fair process, with the signature change being a requirement that staff make certain probative evidence available during the Wells process, say attorneys at Debevoise.
-
March 19, 2026
Prologis, GIC Ink $1.6B Build-To-Suit Logistics JV
Logistics real estate leader Prologis and investor GIC announced Thursday that they have formed a $1.6 billion joint venture to develop and own build-to-suit logistics facilities across major U.S. markets.
-
March 19, 2026
Ex-Workers Ask 11th Circ. To Overturn ERISA Exhaustion Rule
Former workers for a seafood company urged the full Eleventh Circuit to overturn precedent that led a three-judge panel to uphold dismissal of their suit alleging mismanagement of an employee stock ownership plan, arguing the court's strictest-in-the-nation standard on exhausting administrative remedies didn't align with federal benefits law.
Areas of Coverage
- TRANSACTIONS
- Private equity deals valued at $50MM or more
- Venture capital investments of $25MM or more
- Mergers and acquisitions
- Capital investments, including mezzanine and growth capital deals
- Joint ventures involving private equity firms
- Hostile takeovers and leveraged buyouts
- Distressed investment deals
- AGENCIES
- U.S. Commodity Futures Trading Commission
- Federal Trade Commission
- Financial Industry Regulatory Authority
- Public Company Accounting Oversight Board
- U.S. Department of Justice
- U.S. Department of the Treasury
- U.S. Securities and Exchange Commission
- International competition and securities regulators
- POLICY & REGULATION
- Dodd-Frank Act
- Delaware corporate law
- Antitrust and consumer protection controls
- Private equity industry lobbying
- International banking legislation and regulation
- ENFORCEMENT
- Merger reviews
- Second requests
- Challenges and divestitures
- Litigation
- Antitrust suits
- Shareholder disputes
- Corporate governance fights
- Poison pill challenges
- Hostile takeover disputes
- Privacy and consumer protection suits
- Bankruptcy proceedings involving private equity stakeholders
- PROFILES
- Personnel moves
- Profiles of private equity practices
Readership
- Private equity lawyers at top law firms
- Corporate counsel and compliance officers at Fortune 1000 companies
- Executives and attorneys in the private equity industry
- Information experts at law firms, agencies, and companies
- Policymakers at federal and state agencies
- Judges and court staff across the U.S.
- Professors, students, and library staff at every accredited law school in the U.S.
- Attorney and law firm marketing professionals